Incyte's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Incyte in the third quarter 2026?
Incyte Corporation achieved a return on average equity (ROE) of 7.08 % in its third quarter 2026, this is above INCY's average return on equity of -26.31%.
Incyte Corporations equity during the 12 months ending in the third quarter 2026 are valued at $5 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Medical Laboratories industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 114 to 408.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	21.32 %	52.11 %	53.31 %	49.89 %	-
Y / Y Net Income Change	-	44.59 %	91.73 %	48.74 %	298.45 %
Net Income (TTM) in Millions	403	1,612	1,432	1,287	1,189
Return On Equity (TTM)	7.08 %	29.6 %	29.2 %	29.15 %	29.83 %
INCY's Total Ranking	# 408	# 114	# 339	#	#
Equity (TTM) in Millions	5,643	6,344	5,623	5,167	4,651
Seq. Equity Change	-11.06 %	12.83 %	8.81 %	11.1 %	11.52 %
Seq. Net Income Change	-	93.06 %	1.35 %	-29.44 %	4.73 %

Back to INCY Management Effectiveness >> INCY's 5 Years Annual ROE >> Compare INCY ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 10
Sector	# 158
Overall	# 408

Return On Equity Statistics
High	Average	Low
56.49 %	-26.31 %	-1640.46 %
(Sep 30 2016)		(Sep 30 2015)

INCY Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	5,167	3,448	5,190	4,370	3,770
Y / Y Equity Change	49.89 %	-33.57 %	18.76 %	15.92 %	44.37 %
Net Income in Millions	1,287	33	598	341	949
Y / Y Net Income Change	3844.96 %	-94.54 %	75.42 %	-64.09 %	-
Return On Equity	24.9 %	0.95 %	11.51 %	7.8 %	25.16 %

Back to INCY Management Effectiveness >> INCY's 5 Years Annual ROE >> Compare INCY ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 24.9 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
INCY's' Return on Equity at Yahoo Finance
INCY's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for INCY's Competitors
Subscribers only: Roe for Incyte's Suppliers
Subscribers only: Return On Equity for INCY's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Pediatrix Medical Group Inc	17.28 %
Kiniksa Pharmaceuticals International Plc	17.27 %
Krystal Biotech Inc	17.02 %
Intuitive Surgical Inc	16.99 %
Ensign Group Inc	16.62 %
Lemaitre Vascular Inc	15.81 %
Stryker Corp	15.61 %
Quest Diagnostics Inc	15.22 %
Regeneron Pharmaceuticals Inc	15.07 %
Bio rad Laboratories Inc	14.07 %
Boston Scientific Corporation	13.75 %
Inspire Medical Systems inc	12.49 %
Haemonetics Corporation	12.07 %
Labcorp Holdings Inc	11.55 %
Henry Schein Inc	11.29 %
Medinotec Inc	10.97 %
Tactile Systems Technology Inc	10.73 %
Penumbra Inc	10.44 %
Teleflex Incorporated	9.67 %
Merit Medical Systems Inc	9.65 %
U S Physical Therapy Inc	9.48 %
Pacific Health Care Organization Inc	8.10 %
Incyte Corporation	7.08 %
Conmed Corporation	7.07 %
Teva Pharmaceutical Industries Limited	6.37 %
Integer Holdings Corporation	6.02 %
Avantor Inc	5.96 %
Ligand Pharmaceuticals Incorporated	5.22 %
Lifestance Health Group Inc	4.82 %
Jazz Pharmaceuticals Plc	4.62 %

Date modified: 2026-10-30T16:59:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.